(RGLS) Regulus Therapeutics - Performance 21.6% in 12m
Compare RGLS with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
-53.48%
#80 in Group
Rel. Strength
77.44%
#1813 in Universe
Total Return 12m
21.59%
#36 in Group
Total Return 5y
-41.28%
#57 in Group
P/E -
(?) Percentile in Group
P/E Forward -
(?) Percentile in Group
PEG -0.04
54th Percentile in Group
FCF Yield -53.74%
10th Percentile in Group
12m Total Return: RGLS (21.6%) vs XBI (-2.3%)

5y Drawdown (Underwater) Chart

Top Performers in Biotechnology
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
---|---|---|---|---|---|---|---|---|
UTHR NASDAQ United Therapeutics |
-8% | 23.5% | 161% | 11.9 | 10.6 | 1.43 | 83.8% | 78.5% |
HLN NYSE Haleon |
2.55% | 23.2% | 41.6% | 24.7 | 20.3 | 1.8 | 27.1% | - |
AMGN NASDAQ Amgen |
-8.48% | 7.43% | 35.1% | 36.6 | 13.3 | 0.94 | -18.8% | -20% |
LONN SW Lonza |
0.56% | 12.5% | 38.1% | 60.7 | 31.7 | 1.15 | 12.6% | -10.3% |
BIM PA Biomerieux |
-1.7% | 17.1% | 0.22% | 31 | 24.2 | 1.45 | -58.7% | -25.1% |
NBIX NASDAQ Neurocrine Biosciences |
-8.13% | -22.5% | 4.98% | 30.8 | 20.4 | 0.27 | 61.5% | 31.6% |
KMDA NASDAQ Kamada |
-5.51% | 32.3% | -8.24% | 24.3 | 22.8 | 0.91 | 47.7% | 3.93% |
ERF PA Eurofins Scientific SE |
6.82% | -5.27% | 21% | 24.3 | 11.7 | 0.58 | -70.8% | -17.1% |
Performance Comparison: RGLS vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for RGLS
Total Return (including Dividends) | RGLS | XBI | S&P 500 |
---|---|---|---|
1 Month | 112.31% | -7.84% | -4.31% |
3 Months | 131.93% | -13.34% | -7.85% |
12 Months | 21.59% | -2.25% | 10.76% |
5 Years | -41.28% | -18.04% | 106.31% |
Trend Score (consistency of price movement) | RGLS | XBI | S&P 500 |
1 Month | 77.6% | -17.6% | -35.6% |
3 Months | 92.7% | -91.9% | -89.7% |
12 Months | -60.5% | -36.5% | 58.3% |
5 Years | -76.8% | -53.3% | 84.2% |
Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
1 Month | #2 | 130% | 122% |
3 Month | #2 | 168% | 152% |
12 Month | #38 | 24.4% | 9.78% |
5 Years | #55 | -28.4% | -71.5% |
FAQs
Does RGLS Regulus Therapeutics outperforms the market?
Yes,
over the last 12 months RGLS made 21.59%, while its related Sector, the SPDR S&P Biotech (XBI) made -2.25%.
Over the last 3 months RGLS made 131.93%, while XBI made -13.34%.
Over the last 3 months RGLS made 131.93%, while XBI made -13.34%.
Performance Comparison RGLS vs Indeces and Sectors
RGLS vs. Indices RGLS is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | 30.2% | 117% | 96.0% | 10.8% |
US NASDAQ 100 | QQQ | 28.2% | 117% | 96.0% | 9.58% |
US Dow Jones Industrial 30 | DIA | 32.2% | 118% | 95.7% | 14.6% |
German DAX 40 | DAX | 32.8% | 116% | 77.5% | -1.92% |
Shanghai Shenzhen CSI 300 | CSI 300 | 36.7% | 116% | 97.4% | 13.0% |
Hongkong Hang Seng | HSI | 32.4% | 115% | 94.1% | 7.57% |
India NIFTY 50 | INDA | 37.6% | 111% | 94.4% | 19.8% |
Brasil Bovespa | EWZ | 30.4% | 110% | 91.5% | 27.1% |
RGLS vs. Sectors RGLS is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | 30.3% | 118% | 87.2% | -0.81% |
Consumer Discretionary | XLY | 27.8% | 116% | 92.8% | 7.24% |
Consumer Staples | XLP | 37.6% | 110% | 90.7% | 12.1% |
Energy | XLE | 33.5% | 124% | 98.4% | 33.5% |
Financial | XLF | 32.1% | 117% | 87.9% | 2.29% |
Health Care | XLV | 33.2% | 117% | 98.0% | 21.3% |
Industrial | XLI | 32.0% | 116% | 95.6% | 14.7% |
Materials | XLB | 33.4% | 117% | 103% | 26.9% |
Real Estate | XLRE | 35.0% | 114% | 98.1% | 6.47% |
Technology | XLK | 26.4% | 117% | 101% | 15.4% |
Utilities | XLU | 34.3% | 111% | 92.9% | 1.15% |
Aerospace & Defense | XAR | 30.6% | 113% | 84.7% | -5.39% |
Biotech | XBI | 31.0% | 120% | 109% | 23.8% |
Homebuilder | XHB | 31.9% | 118% | 111% | 29.6% |
Retail | XRT | 33.0% | 115% | 100% | 25.2% |